Journal
VIRULENCE
Volume 6, Issue 4, Pages 362-371Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21505594.2015.1039885
Keywords
Candida albicans; antifungal drug; drug resistance; virulence factors; synergy
Categories
Funding
- China Ocean Mineral Resources R D Association [DY125-15-T-07]
- National Program on Key Basic Research Project (973 program) [2013CB734000]
- National Natural Science Foundation of China [31430002, 31400090, 31320103911, 81302678, 31125002]
- Ministry of Science and Technology of the People's Republic of China [2011ZX09102-011-11, 2013ZX10005004-005]
- NNF Center for Biosustainability [New Bioactive Compounds] Funding Source: researchfish
- Novo Nordisk Fonden [NNF10CC1016517] Funding Source: researchfish
Ask authors/readers for more resources
Candida albicans, one of the pathogenic Candida species, causes high mortality rate in immunocompromised and high-risk surgical patients. In the last decade, only one new class of antifungal drug echinocandin was applied. The increased therapy failures, such as the one caused by multi-drug resistance, demand innovative strategies for new effective antifungal drugs. Synergistic combinations of antifungals and anti-virulence agents highlight the pragmatic strategy to reduce the development of drug resistant and potentially repurpose known antifungals, which bypass the costly and time-consuming pipeline of new drug development. Anti-virulence and synergistic combination provide new options for antifungal drug discovery by counteracting the difficulty or failure of traditional therapy for fungal infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available